This analysis supports the identification of metabolically distinct subtypes of NB: MYCN amplified metastatic NB exhibiting elevated glycolytic gene expression, consistent with a Warburg metabolic profile, and non‐high‐risk NB characterised by lower glycolytic activity and conserved or increased ketolytic gene expression, consistent with a less proliferative metabolic phenotype. The gene discussed is MYCN; the disease is neuroblastoma.